Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

WALTHAM, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. The grants are comprised of $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF). The grants will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.

"We are very pleased to receive support from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Foundation and the National Ataxia Foundation, national organizations recognized for their commitment to innovative research aimed at providing new therapeutic options for patients," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We believe that establishing partnerships with these non-profit organizations will result in a number of mutual benefits as the program matures and we prepare for human clinical trials."

Friedreich's ataxia is an inherited neurodegenerative disease in which a single gene defect results in inadequate production of the protein frataxin, leading to progressive damage to the nervous system and loss of muscle function. Prior research has demonstrated that production of frataxin protein can be increased in tissue samples and animal models by a family of compounds, suggesting the potential utility of these compounds in slowing or halting disease progression.

In April 2007, Re
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Junto Health, a company that helps major ... new technology solutions, today announced the launch of a ... in health care policy consulting. Working together with SPG, ... innovation process while, at the same time, they are ... health care finance and the delivery of health care ...
(Date:7/24/2015)... July 24, 2015 Ryan & Maniskas, LLP ... United States District Court for the Northern District of ... entities that purchased the common stock of Avalanche Biotechnologies, Inc. ... 31, 2014 and June 15, 2015, inclusive (the "Class Period"). ... 2015, move the Court for appointment as a lead plaintiff ...
(Date:7/24/2015)... July 24, 2015 Origin Agritech Limited (NASDAQ GS: ... seeds in China , today announced that ... year 2015 ended June 30, 2015, before the market opens ... host a teleconference on August 5th, 2015, at 9:00 a.m. ... to discuss the results. To participate in the call, please ...
(Date:7/23/2015)... ... , ... The health and wellness of brain tumor caregivers, often a spouse, ... diagnosis. The American Brain Tumor Association presents interactive sessions that address shifting the mindset ... 24-25 in Chicago. , “We have understood for a long-time now that caregivers ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3
... ATLANTA, Feb. 5 CryoLife, Inc. (NYSE: CRY ... today that 2008 fourth quarter and year end financial results ... Company will hold a teleconference call and live webcast at ... results, followed by a question and answer session hosted by ...
... Isis, first kidney-targeted antisense drug for type 2 diabetes ... Inc. (Nasdaq: ISIS ) announced today it ... antisense drug that inhibits the production of sodium dependent ... major transporter responsible for glucose re-absorption in the kidney. ...
... 4 Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX ), a biopharmaceutical ... will be speaking at the 11th Annual,BIO CEO & Investor Conference. ... Presentation:, Date: Monday, February 9, 2009, ... Location: Waldorf Astoria, Astor Room, New York, ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 3Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 4
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/24/2015)... Switzerland , June 24, 2015 ... partnership with emerging biometric password solution one face ... one face in, entering ... a ground-breaking and affordable multifactor-authentication biometric answer to ... recognition technology, provided in partnership with KeyLemon, one ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 4, 2010) -- In a leap toward making stem cell ... at Weill Cornell Medical College have discovered that endothelial cells, ... growth factors that can grow copious amounts of adult stem ... now, adult stem cell cultures would die within four or ...
... Scripps Institution of Oceanography, UC San Diego, paleoceanographer Richard Norris ... impact really did kill off dinosaurs and myriad other organisms ... researchers are authors of a review paper being released Friday ... salvo in an ongoing controversy over the cause of the ...
... environmental health scientists will share their latest scientific ... training opportunities, receive input on future research priorities, ... annual meeting. Staff from the National ... the National Institutes of Health, and the National ...
Cached Biology News:Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 2Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 3Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 5Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 630 years later, what killed the dinosaurs is revisited 230 years later, what killed the dinosaurs is revisited 3Leading toxicologists highlight advances to safeguard public health 2Leading toxicologists highlight advances to safeguard public health 3Leading toxicologists highlight advances to safeguard public health 4
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: